Introduction
This summary offers a national overview of numerous aspects of solid organ transplantation in the United States, produced as part of the 2004 OPTN/SRTR Annual Report. The Annual Report is prepared by the Scientific Registry of Transplant Recipients (SRTR) in collaboration with the Organ Procurement and Transplantation Network (OPTN) under contract with the Health Resources and Services Administration (HRSA). One of the purposes of providing such a detailed Annual Report is to gather the extensive and varied knowledge on the current state of transplantation in a single publication. This publication is intended to be useful for patients, the transplant community, the public and the Federal Government; its goal is to improve patient care and enhance equitable access to transplantation.
Note on sources:
The articles in this report are based on the reference tables in the 2004 OPTN/SRTR Annual Report, which are not included in this publication. Many relevant data appear in the tables included here; other tables from the Annual Report that serve as the basis for this article include the following: Tables 1.1, 1.3, 1.5-1.7, 1.10, 1.11a, 1.13, 2.1, 2.2, 5. 2, 5.4, 5.6a-13.6a, 5.6b-13.6b, 5.6d-13.6d, 5.9a-c, 8.9, 9.1, 9.3, 9.7a, 9.12a, 10.7, 11.1, 11.3, 11.7, 12.1, 12.11, 12.13a, 13.1 and 13.11 . All of these tables may be found online at http://www.ustransplant.org.
Funding: The Scientific Registry of Transplant Recipients (SRTR)
is funded by contract number 231-00-0116 from the Health Resources and Services Administration (HRSA), US Department of Health and Human Services. The views expressed herein are those of the authors and not necessarily those of the U.S. Government. This is a US Government-sponsored work. There are no restrictions on its use.
Ten groups of authors drawn from across the U.S. transplant community, all experts in their fields, have produced a wealth of information in 10 peer-reviewed articles based on new analyses, figures and tables. The text of the following articles is based to a large extent on the detailed reference tables of the Annual Report, which have been prepared by the University Renal Research and Education Association (URREA), the contractor for the SRTR since October 2000. These 10 articles and reference tables are included in the Annual Report and are available as a compact disc. They may also be found online at www.ustransplant.org and www.optn.org.
Summary statistics for 2002-2003 on transplantation in the United States
During 2003, more than 25 000 organs were transplanted in the United States-over 18 000 from deceased donors and almost 7000 from living donors. Compared to data from the prior year (2002), these numbers reflect an increase in the number of deceased donor transplants by 2.2% overall and by 1.9% for deceased donors; a greater increase was noted for living donors (2.9%), as shown in Table 1 . During the same period, more than 7000 patients were reported to have died while waiting for a transplant. The number of deaths on the waiting list did not change substantially from 2002 to 2003; however, there was a decrease in the overall death rate because of the increase in waiting list size.
The waiting list for deceased donor transplants has increased at more than twice the rate of increase in the number of transplants during the past year, by 5.1% versus 1.9% (Table 2) . This large increase is a continuation from earlier years and provides a strong indication of the ever-increasing demand for organs. The total number of patients on the waiting list reached almost 86 500 in 2003. Table 2 demonstrates the increases in numbers of candidates by organ, comparing the numbers of patients on the waiting list in 2002 and 2003. When the number of patients waiting for a transplant increases, it demonstrates that the demand exceeds the supply-more patients are added to the list than are removed from it. Hopefully, these removals occur because of transplantation, but they also represent death and (occasionally) recovery from organ failure. The table shows clearly that the demand for kidney and pancreas transplants increased steeply; lung and liver transplant demand also increased, though to a lesser degree. By contrast, the number of patients awaiting heart, heartlung and intestine transplants decreased in 2003 compared to the prior year. Longer time trends for the past decade are demonstrated for each organ in the organ-specific articles that follow.
As a consequence of the steeply increasing demand for transplants and slowly increasing supply of organs, the waiting list is getting longer and the waiting times for transplant candidates, which are already long, are getting longer. The urgent need for more donor organs is suggested by many of the articles in this report; it is particularly pronounced for kidneys, pancreata and livers. Two critical measures describe the key outcomes after transplantation: the function of the transplanted graft and survival of the transplant recipient. Patient survival after transplantation has been generally improving over time. Table 3 shows by organ the results for patient survival for the most recent years for which 1-or 5-year follow-ups are available (the former for recipients during 2001-2002 and the latter for recipients during 1997-1998). Corresponding numbers from cohorts transplanted 1 year earlier are also shown, for comparison. One-year patient survival for kidney and pancreas transplants were around 95-97%; corresponding survival rates were about 86% for liver and heart, about 80% for lung and intestine and lowest for combined heart-lung recipients.
Functional survival of the transplanted organ, i.e. graft survival, has improved substantially over the past decade and has been relatively stable in recent years. Table 4 shows the 1-and 5-year graft survival results for each organ for the same most recent years as for patient survival. Compared to the data for patient survival, figures for graft failure are usually lower. This is due to the fact that patients may survive a graft failure by receiving a timely second transplant, by returning to dialysis (for kidney transplant recipients), or by returning to insulin therapy (for pancreas transplant recipients). The survival trends observed in Tables 3 and  4 show generally small improvements from the prior year. More detailed trends over longer time spans are provided in the organ-specific articles of this report.
The articles in the 2004 SRTR Report on the State of Transplantation
The articles in this report encompass a broad range of topics related to solid organ transplantation in the United States. This year, in addition to updated information on transplantation trends and practices, recent and significant allocation policy issues are discussed within the three major organ areas-kidney and pancreas, liver and intestine, and heart and lung. Throughout this report, the SRTR and its expert collaborators continue to provide timely, relevant interpretation and analysis of the transplant data provided through the OPTN and supplemental sources.
Articles on data sources and analytical approaches provide useful background information regarding analysis design and the statistical methods used to produce the Annual Report, the center-specific reports and other SRTR analyses. These detailed discussions of methods are essential, as they apply to all the articles in this issue, as well as more generally to a wider body of research.
The report concludes with a special focus article on new and useful methods for evaluating organ procurement organization (OPO) performance. Important issues regarding accuracy of death reporting, variations in OPO practices and methods to account for geographic differences in the potential donor supply are discussed.
Summaries and data highlights of each article follow.
Transplant data: sources, collection, and research considerations, 2004
A brief review of the scope of data available from the SRTR is included in this article, which seeks to outline up-to-date information about caveats based on extra ascertainment and patterns in data submission. The discussion of extra ascertainment of outcomes is expanded this year to examine graft failure events for kidneys on the basis of Medicare data to ascertain return to dialysis, as well as extra ascertainment of deaths. Finally, the effects of changes in data submission patterns resulting from OPTN data collection improvements and feedback reporting by both the SRTR and OPTN are emphasized as issues that should be carefully considered when choosing cohorts and data sources for analysis. r Maintenance immunosuppression has also seen an ongoing evolution. Calcineurin inhibitors continue to be used for most recipients, with a continuing shift in the calcineurin inhibitor used from cyclosporine to tacrolimus (this shift was less pronounced for heart transplantation). In 2003, 67% of kidney, 84% of SPK, 81% of PAK, 81% of pancreas transplant alone (PTA), 66% of lung and 41% of heart transplant patients received tacrolimus. An even more noticeable shift was seen in the type of antimetabolite used, from azathioprine to mycophenolate mofetil; the latter remains the most widely used immunosuppressive agent in solid organ transplantation: In 2003, 81% of kidney, 82% of SPK, 85% of PAK, 71% of PTA and 82% of heart recipients received mycophenolate mofetil as maintenance immunosuppression prior to hospital discharge.
r Corticosteroids continue to be used as maintenance immunosuppression for most recipients prior to discharge from their initial transplant hospitalization (in 2003, for 95% of lung, 93% of heart, 85% of kidney, 84% of SPK, 82% of liver, 81% of PAK and 62% of PTA recipients). However, the fact that these percentages are less than 100% indicate that efforts of steroid avoidance and near-avoidance protocols are starting to have an impact across all organs.
r The incidence of acute rejection in the first year after transplantation continues to decline. This decline partly explains the observed improvement in graft survival. Steroids and antibody therapy continue to be used as the mainstay in the treatment of acute rejection.
Pediatric transplantation, 1994-2003
Pediatric organ transplant recipients differ from their adult counterparts in several important aspects, including the underlying etiology of organ failure, the complexity of the surgical procedures, the pharmacokinetic properties of common immunosuppressants, the immune response following organ transplantation, the measures of success of the transplant procedure, the number and degree of comorbid conditions and the susceptibility to post-transplant complications, especially infectious diseases. Thus, specialized pediatric organ transplant programs have been developed to better address these problems. The transplant community has responded to the unique needs of children and has provided them special consideration in the allocation of deceased donor organs. This article summarizes these provisions. An important outcome of these programs, provisions and protocols has been that children frequently achieve the highest success with organ transplantation, with the outcomes for kidney, liver and heart transplantation ranking among the best. This report also demonstrates that improvement is still needed in adolescent outcomes, in pediatric outcomes of intestinal transplants and in waiting list mortality for pediatric heart and lung candidates.
The number of transplants in children has increased only by 16% from 1994 to 2003 while the number of total transplants has grown by 39%. The increase in pediatric transplants reflects the relatively high percentage of living donor organs directed toward children and the preference provided for them in deceased donor organ allocation, which is described further in this article.
Current status of kidney and pancreas transplantation in the United States, 1994-2003
This article reviews the extensive data collected on kidney and pancreas transplantation during 2003 in the context of trends over the past decade. Characteristics of wait-listed candidates are discussed, followed by assessments of transplant recipient characteristics and of recipient and allograft survival. Characteristics of ECD and ECD kidney recipient outcomes are also described. Sections on pancreas transplantation discuss trends for SPK, PAK and PTA. Important changes have been made in the kidney allocation algorithm in the past 2 years that are also addressed.
Notable highlights on trends include the following:
r The annual number of new wait-listed registrants under the age of 50 has remained fairly stable since 1994, but the number of new registrants aged 50-64 has doubled, and the number of new registrants over the age of 64 has more than tripled during the past decade. Quantifying organ donation rates by donation service area Previous measures of OPO performance based on population counts have been deemed inadequate, and the need for new methods has been widely accepted. The SRTR has been making significant progress in this area and has devoted this special focus article to explaining recent developments in the OPO performance evaluation methodology.
As a replacement for the previously established measure of OPO performance-donors per million population-the utilization of eligible deaths as a national metric has yielded promising results for understanding variations in donation rates among the DSA assigned to each OPO. A major improvement uses 'notifiable deaths' as a denominator describing a standardized maximal pool of potential donors. Notifiable deaths are defined as in-hospital deaths among ages 70 years and under, excluding certain diagnosis codes related to infections, cancers, etc. A most proximal denominator for determining donation rates is 'eligible deaths', which include only those deaths that meet the criteria for organ donation upon initial assessment. Neither of these measures is based on the population of a geographic unit, but on more or less restricted upper limits of deaths that could be potential donors in any one locale (e.g. hospital or OPO). The inherent strengths and weaknesses of metrics such as donors per eligible deaths, donors per notifiable deaths and the number of organs per donor are discussed in detail in this article.
Notification rates and donation rates vary widely in the DSAs of the OPOs. Similarly, SRTR data show that OPO experience with ECD and DCD organ distribution varies to a large degree. The Organ Donation Breakthrough Collaborative mentioned in the organ donation article has contributed to this area of research by affirming a set of standard metrics of organ donor analysis to evaluate donation and considering best practices at the OPO and donor hospitals.
Conclusion
This report provides a great deal of information on the current state of transplantation in the United States. The observed time trends over the past decade and the most recent 2 years give important perspectives on many areas of organ donation, immunosuppression, organ-specific issues and overall outcomes. Numerous impressive improvements are documented in this report, as are areas that need to be addressed with great urgency-such as enhancing organ donation to reduce the annually increasing gap between available organs and the growing need for life-saving transplantation.
